Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for perioperative depressive symptoms in hip surgery patients
ChiCTR2200065589Phase 4Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Capital Medical University. Primary endpoint: Response rate to treatment of depressive symptoms on the first postoperative day. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2200065589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065589.